By Mill Chart
Last update: Oct 30, 2023
Our stock screener has singled out BRISTOL-MYERS SQUIBB CO (NYSE:BMY) as a promising choice for dividend investors. NYSE:BMY not only scores well in profitability, solvency, and liquidity but also offers a decent dividend. We'll explore this further.
To gauge a stock's dividend quality, ChartMill utilizes a Dividend Rating ranging from 0 to 10. This comprehensive assessment considers various dividend aspects, including yield, history, growth, and sustainability. NYSE:BMY has achieved a 7 out of 10:
ChartMill employs its own Health Rating for stock assessment. This rating, ranging from 0 to 10, is calculated by examining various liquidity and solvency ratios. In the case of NYSE:BMY, the assigned 5 reflects its health status:
ChartMill assigns a proprietary Profitability Rating to each stock. The score is computed by evaluating various profitability ratios and margins and ranges from 0 to 10. NYSE:BMY was assigned a score of 8 for profitability:
More Best Dividend stocks can be found in our Best Dividend screener.
Our latest full fundamental report of BMY contains the most current fundamental analsysis.
This article should in no way be interpreted as advice in any way. The article is based on the observed metrics at the time of writing, but you should always make your own analysis and trade or invest at your own responsibility.
BRISTOL-MYERS SQUIBB CO
NYSE:BMY (4/18/2024, 7:04:00 PM)
Premarket: 48.2 -0.1 (-0.21%)48.3
+0.46 (+0.96%)
Make the most of a modest investment by putting it into Intuitive Surgical, Bristol Myers Squibb, and Novo Nordisk.
Make the most of a modest investment by putting it into Intuitive Surgical, Bristol Myers Squibb, and Novo Nordisk.
If you want to outperform the S&P 500, consider these undervalued dividend stocks for juicy yields and high total return potential.
These income stocks look like good options at current levels.
The economy, and pharma industry, are projected to grow massively. You should invest in these top three pharma stocks.
InvestorPlace - Stock Market News, Stock Advice & Trading Tips The future of the U.S. economy appears promising, with robust growth and strong...
The company was testing a potential treatment for schizophrenia in rabbits, but found a notable side effect.
Bristol Myers Squibb stock sports an attractive valuation and dividend yield. Is it a more compelling buy than the Vanguard S&P 500 ETF?
Bristol Myers Squibb stock sports an attractive valuation and dividend yield. Is it a more compelling buy than the Vanguard S&P 500 ETF?
Merck's shares are trading in bargain territory. Are they a better growth play than this popular Vanguard fund?
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Bristol-Myers Squibb Company ("Bristol Myers" or the "Company") (NYSE: BMY)....